EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Comparison of the efficacy of pre-transplant and post-transplant antithymocyte globulin combined with post-transplant cyclophosphamide for graft- versus -host disease prophylaxis in myeloablative haploidentical peripheral blood stem cell transplantation

Xuelian Jin, Tian Dong, Jie Ji, Zhigang Liu, Pu Kuang, Jian Li, Yu Wu, Juan Xu, Zerong Wang, Jiajia Zeng, Zilin Xiong, Xinchuan Chen iD

Cell Transplantation · 2026-06 · 35

DOI: 10.1177/09636897261454024 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Cell Transplantation, online erschienen am 01.06.2026. Verfasst von Xuelian Jin und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Graft vs Host Disease, Cyclophosphamide, Antilymphocyte Serum, Peripheral Blood Stem Cell Transplantation. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Clinical Research Incubation Project, West China Hospital, Sichuan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although post-transplant cyclophosphamide (PTCy) is widely used to prevent graft-versus-host disease (GVHD), its protective effect remains inadequate in patients undergoing myeloablative haploidentical peripheral blood stem cell transplantation (haplo-PBSCT). We retrospectively evaluated the efficacy of PTCy combined with either pre-transplant or post-transplant antithymocyte globulin (ATG) for GVHD prevention in 114 haplo-PBSCT recipients. The PTCy+FTATG group (n = 74) received ATG at a total dose of 5 mg/kg on days −3 to −1, together with PTCy at 25 mg/kg on days +3 and +4. The PTCy+PTATG group (n = 40) received PTCy at 50 mg/kg on days +3 and +4, followed by ATG at 2.5 mg/kg on day +8. Both univariate and multivariate analyses showed that PTCy+FTATG prophylaxis significantly lowered the risk of grade II–IV acute GVHD (9.5% vs 27.5% [HR 0.24; 95% CI: 0.10–0.59; P = 0.002]) and grade III–IV acute GVHD (5.4% vs 17.5% [HR 0.19; 95% CI: 0.07–0.54; P = 0.002]). The 2-year cumulative incidence of chronic GVHD was 16.7% in the PTCy+FTATG group and 27.5% in the PTCy+PTATG group ( P = 0.15). At 2 years, overall survival (OS), progression-free survival (PFS), and graft-versus-host disease-free relapse-free survival (GRFS) were 87.8% vs 72.5% ( P = 0.04), 82.2% vs 65.0% ( P = 0.03), and 78.1% vs 55.0% ( P = 0.005), respectively. These results suggest that half-dose PTCy combined with low-dose pre-transplant ATG may be a promising strategy for GVHD prophylaxis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graft vs Host DiseaseCyclophosphamideAntilymphocyte SerumPeripheral Blood Stem Cell TransplantationHumansFemaleMaleAdultAdolescentMiddle AgedRetrospective StudiesYoung AdultChildTransplantation ConditioningTransplantation, Haploidentical

Stichwörter der Autor:innen

antithymocyte globulingraft-versus-host diseasehaploidenticalhematopoietic cell transplantationpost-transplant cyclophosphamideprophylaxis

Substanzen

CyclophosphamideAntilymphocyte Serum

Autor:innen und Institutionen

  • Department of Hematology, West China Hospital, Sichuan University, Chengdu, China.

ORCID-Profile: Xinchuan Chen

Förderung

  • Clinical Research Incubation Project
  • West China Hospital, Sichuan University

Zitieren

APA

Jin, X., Dong, T., Ji, J., Liu, Z., Kuang, P., Li, J., Wu, Y., Xu, J., Wang, Z., Zeng, J., Xiong, Z., & Chen, X. (2026). Comparison of the efficacy of pre-transplant and post-transplant antithymocyte globulin combined with post-transplant cyclophosphamide for graft- versus -host disease prophylaxis in myeloablative haploidentical peripheral blood stem cell transplantation. Cell Transplantation, 35. https://doi.org/10.1177/09636897261454024

Vancouver

Jin X, Dong T, Ji J, Liu Z, Kuang P, Li J, et al. Comparison of the efficacy of pre-transplant and post-transplant antithymocyte globulin combined with post-transplant cyclophosphamide for graft- versus -host disease prophylaxis in myeloablative haploidentical peripheral blood stem cell transplantation. Cell Transplantation. 2026;35. doi:10.1177/09636897261454024

BibTeX
@article{Jin2026,
  author = {Jin, Xuelian and Dong, Tian and Ji, Jie and Liu, Zhigang and Kuang, Pu and Li, Jian and Wu, Yu and Xu, Juan and Wang, Zerong and Zeng, Jiajia and Xiong, Zilin and Chen, Xinchuan},
  title = {Comparison of the efficacy of pre-transplant and post-transplant antithymocyte globulin combined with post-transplant cyclophosphamide for graft- versus -host disease prophylaxis in myeloablative haploidentical peripheral blood stem cell transplantation},
  journal = {Cell Transplantation},
  year = {2026},
  volume = {35},
  doi = {10.1177/09636897261454024}
}
Kostenlos starten →